|
Treatment of lower-risk myelodysplastic syndromes |
Feb 2025 |
Haematologica |
Myelodysplastic Syndromes (MDS) |
|
Treatment of high-risk myelodysplastic syndromes |
Feb 2025 |
Haematologica |
Myelodysplastic Syndromes (MDS) |
|
Diagnosis of myelodysplastic syndromes: the classic and the novel |
Feb 2025 |
Haematologica |
Myelodysplastic Syndromes (MDS) |
|
Genome sequencing in the management of myelodysplastic syndromes and related disorders |
Feb 2025 |
Haematologica |
Myelodysplastic Syndromes (MDS) |
|
Detectable mutations precede late myeloid neoplasia in aplastic anemia |
Feb 2021 |
Haematologica |
Aplastic Anemia |
|
Is blood transfusion safe during the COVID-19 pandemic? |
Sep 2020 |
Future Science OA |
Aplastic Anemia, Myelodysplastic Syndromes (MDS), Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Luspatercept in the treatment of lower-risk myelodysplastic syndromes |
Jan 2021 |
Future Oncology (London, England) |
Myelodysplastic Syndromes (MDS) |
|
Targeting the Microenvironment in MDS: The Final Frontier |
Jul 2020 |
Frontiers in Pharmacology |
Myelodysplastic Syndromes (MDS) |
|
The role of androgen therapy in acquired aplastic anemia and other bone marrow failure syndromes |
May 2023 |
Frontiers in Oncology |
Aplastic Anemia |
|
How we diagnose Myelodysplastic syndromes |
Sep 2024 |
Frontiers in Oncology |
Myelodysplastic Syndromes (MDS) |
